

### RoXsta™ Update:

#### Bovine Study Commences with Blood Samples Collected for Analysis

- **Study commenced to assess the potential of RoXsta™ antioxidant system to determine threshold levels of oxidative stress in the bovine and potential correlations with reproductive performance**
- **Bloods collected with frozen samples ready for analysis in January 2025**
- **Preliminary pregnancy results expected late February 2025**
- **If initial findings are positive, the study could lead to a larger-scale clinical trial in Autumn 2025, in collaboration with the University of Newcastle**

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to advise the scoping study to assess the potential of RoXsta™ System, to determine threshold levels of oxidative stress in the bovine and potential reproductive performance, has commenced as scheduled.

As part of the study, blood samples have been successfully collected and are now stored in a -80°C freezer, ensuring their integrity for detailed analysis which is set to commence in January 2025. This milestone marks an essential step in advancing the Company’s research into oxidative stress thresholds and their impact on bovine reproductive performance.

The study, being conducted at a commercial cattle operation in New South Wales, involves the analysis of blood and plasma samples from 50 impregnated heifers. These samples were collected approximately one month after artificial insemination, coinciding with critical stages of foetal development.

**David Ali, Managing Director and CEO of Memphasys, commented:**

*“We are pleased to confirm the timely collection and storage of these blood samples, a critical component in our assessment of the RoXsta™ System’s applications in agriculture. This study represents an important opportunity to develop innovative solutions for improving livestock productivity, with potential benefits for the farming industry and broader agricultural sector.*

*“The analysis aims to correlate antioxidant activity with reproductive success, potentially informing ethical and effective herd management strategies. Preliminary findings are expected to be shared alongside the study’s broader outcomes in early 2025.”*

This announcement has been approved for release by the Board of Memphasys Limited.

**ENDS**

For personal use only

**For further information, please contact:**

Dr David Ali  
Managing Director & CEO  
Memphasys Limited  
Tel: +61 2 8415 7300  
E: [david.ali@memphasys.com](mailto:david.ali@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors  
Tel: +61 433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

**About Memphasys**

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: [www.memphasys.com](http://www.memphasys.com)

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

For personal use only